BeOne Reports Sustained Survival Benefit in First-Line HER2+ Gastroesophageal Cancer Trial
BeOne Medicines said new survival results from the planned second interim and final formal analyses of its Phase 3 HERIZON-GEA-01 trial further confirmed benefit from TEVIMBRA plus ZIIHERA.
Story updates
02:15:46 PM UTC
SquawkNews
BeOne Medicines reported longer-term results from the Phase 3 HERIZON-GEA-01 trial showing sustained overall survival benefit for TEVIMBRA plus ZIIHERA and chemotherapy vs trastuzumab plus chemotherapy in first-line HER2+ GEA after 35.3 months’ follow-up.Material DetailsContext by AI AnalystThis is…